InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,543.22
(
1.61%
)
US TECH 100
19,002.00
(
2.66%
)
Dow Jones
40,563.06
(
1.39%
)
Brent Oil
80.41
(
-0.09%
)
Bitcoin
57,193.38
(
-0.60%
)
Post# of 252897
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120287
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 11/16/2007 5:04:59 PM

Friday, November 16, 2007 5:04:59 PM

Post# of 252897
MNTA – This 2005 PR on the business goals in FoB’s is
being posted for archival purposes. MNTA did in fact ink an
FoB partnership with NVS in 2006 (#msg-12222305) that is
separate from the Lovenox partnership.

http://ir.momentapharma.com/releasedetail.cfm?ReleaseID=243158

>>
Momenta Pharmaceuticals Announces Goals for Glycoprotein Program

CAMBRIDGE, Mass., Jan 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its goals relating to the application of its proprietary technology to therapeutic protein drugs containing sugars. Momenta's goals for its glycoprotein program in 2005 are to characterize the sugars on multiple glycoprotein drugs and to establish a glycoprotein product partnership.

"We believe that we have an opportunity to take our proprietary capability to characterize complex sugars and apply it to the sizeable market of glycoproteins," said Alan Crane, Chairman and CEO of Momenta. The global market for therapeutic proteins exceeded $33 billion in 2003. Given that most of the leading marketed therapeutic proteins and antibodies are glycosylated, or coated with complex sugars, Momenta believes there is a substantial opportunity for its characterization technology to be applied to analyze major marketed products. To date, it has not been possible to thoroughly characterize the sugars on glycoproteins due to lack of available technology. Glycosylation determines critical product properties, including efficacy, safety, specificity, half-life, and immunogenicity.

Momenta's characterization capabilities for glycoproteins can be applied to pursue multiple product and partnering opportunities, including enabling characterization-based life cycle management by better understanding existing marketed products, facilitating follow-on or generic versions of glycoproteins, or creating improved versions of glycoproteins through rational engineering.

"We believe that the application of our characterization technology to glycoproteins significantly broadens our product opportunities and will effectively complement our existing portfolio of heparin-based products such as M-Enoxaparin, M-Dalteparin, and M118," concluded Mr. Crane.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up